MDS Nordion in Partnership With Texas Company

MDS Nordion of Kanata has entered into a research and development partnership with Macrocyclics Inc. to develop innovative, bifunctional chelates for use in molecular imaging and targeted therapeutic drugs. Bifunctional chelates are chemical compounds used to secure a radioisotope to a molecular targeting agent such as a monoclonal antibody, peptide, or other molecules specific for biologic receptors. The use of molecular targeting molecules is a promising technique that has the potential to significantly improve the ability to diagnose and treat disease, including cancer.

()a href="http://www.ottawabusinessjournal.com/285396147234000.php" target="_blank">Ottawa Business Journal